Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.48 |
| ▸ | MAPT | P10636 | 7/20 | 0.48 |
| ▸ | LMNA | P02545 | 5/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | ALPG | P10696 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL97957 | 0.84 | SMN1; SMN2 (0.66) | SMN1; SMN2ALDH1A1LMNAPKMHTT | |
| SCHEMBL12497021 | 0.82 | ALDH1A1 (0.44) | ALDH1A1MAPTLMNAHTTMAPK1 | |
| SCHEMBL11952999 | 0.81 | MAPT (0.70) | SMN1; SMN2ALDH1A1MAPTLMNAGAA | |
| SCHEMBL7467338 | 0.81 | ALDH1A1 (0.50) | SMN1; SMN2ALDH1A1MAPTLMNAPKM | |
| SCHEMBL9423816 | 0.80 | ALDH1A1 (0.62) | SMN1; SMN2ALDH1A1MAPTLMNAPKM | |
| SCHEMBL3994909 | 0.78 | POLB (0.56) | SMN1; SMN2ALDH1A1MAPTLMNARAB9A | |
| SCHEMBL30008070 | 0.78 | POLB (0.56) | SMN1; SMN2ALDH1A1MAPTLMNARAB9A | |
| SCHEMBL4678055 | 0.77 | CA2 (0.39) | SMN1; SMN2ALDH1A1MAPTLMNAHTT | |
| SCHEMBL9153926 | 0.77 | ALDH1A1 (0.58) | SMN1; SMN2ALDH1A1MAPTLMNAHTT | |
| SCHEMBL7475005 | 0.76 | ALDH1A1 (0.41) | SMN1; SMN2ALDH1A1MAPTLMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050032858-A1 | Novel heterocyclic compound and anti-inflamatory agent | NIPPON SODA CO., LTD. (JP) | 2005-02-10 | — | — | US | disclosed |
| EP-1435353-A1 | NOVEL HETEROCYCLIC COMPOUND AND ANTI-INFLAMMATORY AGENT | NIPPON SODA CO., LTD. (JP) | 2004-07-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032858-A1 | Novel heterocyclic compound and anti-inflamatory agent | TLR5, IRF3, IL4 | SMN1; SMN2 2638/4885ALDH1A1 2547/4885MAPT 4288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.